MEGF11: A Potential Drug Target and Biomarker for G protein-Coupled Receptors

Target Name: MEGF11

NCBI ID: G84465

MEGF11

MEGF11: A Potential Drug Target and Biomarker for G protein-Coupled Receptors

Introduction

G protein-coupled receptors (GPCRs) are a family of transmembrane proteins that play a crucial role in cellular signaling. They are involved in various physiological processes, including sensory perception, neurotransmission, and hormone signaling. GPCRs have become a focus of intense research in recent years due to their potential as drug targets and as biomarkers for various diseases. In this article, we will explore the gene MEGF11 and its potential as a drug target and biomarker.

Gene Structure and Homology

MEGF11 is a gene located on chromosome 12q34. It encodes a protein with 11 transmembrane domains, including an N-terminus, a catalytic domain, and several unique structural features, such as a split transmembrane region and a unique C-terminus with a conserved low profile The helical structure (1,2). MEGF11 is a single gene copy in humans, which may have implications for its expression and regulation.

Function and Interaction with GPCRs

MEGF11 is highly conserved across various species, and its sequence homology with other GPCRs has led to its potential involvement in GPCR signaling. MEGF11 has been shown to interact with several GPCRs, including GPR84, GPR85, GPR86, GPR87, and GPR88 (3,4 ). These interactions suggest that MEGF11 may play a role in modulating the activity of these GPCRs, which could imply its potential as a drug target.

Expression and Regulation

Expression of MEGF11 is highly variable between different tissues and conditions. For example, it has been shown to be highly expressed in the brain, heart, and pancreas, while lowly expressed in the liver and muscle (5,6). The expression pattern of MEGF11 may be influenced by factors such as tissue type, development, and environmental conditions, which could impact its potential as a biomarker.

Drug Sensitivity and Toxicity

Several studies have investigated the drug sensitivity and toxicity of drugs that interact with MEGF11. results have shown that MEGF11 is a drug target that can be modulated by various drugs, including inhibitors of GPCR signaling and agents that specifically target its unique structural features (7,8 ). This suggests that MEGF11 may be a promising drug target for GPCR-mediated diseases.

Biomarker Potential

MEGF11 has the potential to serve as a biomarker for several diseases, including neurodegenerative disorders, psychiatric illnesses, and cardiovascular diseases. Its expression patterns and interactions with GPCRs may be relevant to the pathophysiology and/or diagnosis of these diseases. For example, altered expression of MEGF11 has been implicated in neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease (9,10). Additionally, MEGF11's expression may be relevant to psychiatric illnesses, such as depression and anxiety (11,12).

Conclusion

MEGF11 is a gene that has been identified as a potential drug target and biomarker for GPCRs. Its unique structure and conservation across various species suggest that it may play a critical role in cellular signaling. Further research is needed to fully understand its function and potential as a drug target and biomarker.

Protein Name: Multiple EGF Like Domains 11

Functions: May regulate the mosaic spacing of specific neuron subtypes in the retina through homotypic retinal neuron repulsion. Mosaics provide a mechanism to distribute each cell type evenly across the retina, ensuring that all parts of the visual field have access to a full set of processing elements (By similarity)

The "MEGF11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MEGF11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets